Timber pharmaceuticals announces commencement of nyse american delisting proceedings: common stock expected to begin trading on the otc market

Warren, n.j., nov. 29, 2023 (globe newswire) -- timber pharmaceuticals, inc. ("timber" or the "company") (nyse american: tmbr), a clinical-stage biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases, today announced that the staff of nyse regulation (the “nyse regulation”) has determined to immediately suspend trading in the company's common stock from nyse american, llc (the “nyse american”).
TMBR Ratings Summary
TMBR Quant Ranking